Table 2.

FDA-approved drug showing high binding affinities against protease and RBD of SARS-CoV-2.

6y84				6vw1
Drug name	Formula	DrugBank ID	Glide score	Drug name	Formula	DrugBank ID	Glide score
Acarbose	C25H43NO18	DB00284	−13.139	Framycetin	C23H46N6O13	DB00452	−11.233
Colistin	C52H98N16O13	DB00803	−12.63	Acarbose	C25H43NO18	DB00284	−10.649
Paromomycin	C23H45N5O14	DB01421	−11.579	Paromomycin	C23H45N5O14	DB01421	−10.01
Iotrolan	C37H48I6N6O18	DB09487	−11.001	Plazomicin	C25H48N6O10	DB12615	−9.935
Indium In-111 pentetreotide	C62H80InN12O19S2	DB11835	−10.795	Omadacycline	C29H40N4O7	DB12455	−9.178
Framycetin	C23H46N6O13	DB00452	−10.713	Mangafodipir	C22H30MnN4O14P2	DB06796	−9.089
Lutetium Lu-177 dotatate	C65H87LuN14O19S2	DB13985	−10.607	Flavin adenine dinucleotide	C27H33N9O15P2	DB03147	−8.986
Rutin	C27H30O16	DB01698	−9.853	Ribostamycin	C17H34N4O10	DB03615	−8.781

FDA, US Food and Drug Administration; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.